Results European American SLE patients with high disease activity were differentiated from patients with low disease activity by reduced frequencies of peripheral B cells, specifically naïve B cells (CD27-IgD+CD24 lo) (p=0.0101) and double negative B cells (CD27-IgD-) (p=0.0220), while African American patients with high disease activity had elevated frequencies of memory B cells (CD27 +IgD CD38+) (p<0.05) compared to patients with low disease activity. Several cell subsets had increased expression of activation markers during high disease activity including B cells (p=0.0350) and plasmacytoid dendritic cells (pDCs) (p=0.0435) in European Americans (figure 1A), and neutrophils (p<0.05), pDCs (p=0.005), CD8 +T Cells (p=0.0003) and NKT cells (p=0.0033) in African Americans (figure 1B). Following whole blood stimulation with IFN, African American high disease activity patients were distinguished by reduced ability to activate pSTAT5 in almost all major cell populations (p<0.05), and pSTAT3 in monocytes (p=0.0157), granulocytes (p=0.01) and B cells (p=0.0409) compared to low disease activity patients and controls, possibly due to higher basal levels of activation (figure 1). Further, African American patients with high disease activity had significantly elevated cytokine production at baseline compared to healthy controls and European American SLE patients that translated to a reduced fold change in soluble mediators following stimulation (p<0.01).

Conclusions Our results support a model where race influences heightened SLE disease activity mechanisms with alterations in B cell signaling, and greater dysregulation in phospho-signaling and pro-inflammatory soluble mediators observed in African American patients.

Funding Source(s): NIH (U19AI082714, U19AI082719, U54GM104938, P30GM103510, U01AI101934)

Abstract 288 Figure 1 Clustering of SLE patients by PGA and fibromyalgia severity score (FSS)
**Background** Lupus is a complex, heterogeneous disease. We have developed a conceptual model to characterize SLE activity using two dimensions: Type 1 SLE includes active inflammatory manifestations of SLE, including arthritis, nephritis, and rashes; Type 2 SLE includes fatigue, myalgia, mood disturbance, and cognitive dysfunction, which can persist in the absence of inflammatory findings. We have grouped SLE patients into phenotypic clusters based on the extent of Type 1 and 2 SLE features.

**Methods** Consecutive SLE patients meeting ACR or SLICC criteria in a university rheumatology clinic were included. Patients completed the Systemic Lupus Activity Questionnaire (SLAQ) and the ACR Fibromyalgia (FM) Diagnostic Criteria. The Fibromyalgia Severity Score (FSS) is the sum of the widespread pain (0–19) and symptom severity (0–9) scores. The physicians global assessment (PGA) was also recorded. Patients were grouped into clusters based on PGA (Type 1 SLE) and FSS (Type 2 SLE) using hierarchical clustering with Wards minimum variance method. Differences were estimated by ANOVA and Fishers exact test.

**Results** The 419 SLE patients (92% female; mean age: 45 years) were classified into 7 clusters (figure 1).

- **Minimal SLE:** Clinical Remission (n=85): minimal Type 1 and 2 SLE.
- **Clinical Remission with Fatigue** (n=113): minimal Type 1 and mild Type 2 symptoms of fatigue (70%) and waking unrefreshed (58%).
- **Predominantly Type 1:** Moderate Type 1 SLE (n=56): active Type 1 SLE (43% arthritis, 55% anti-dsDNA+) and minimal Type 2 symptoms.
- **Severe Type 1 SLE** (n=31): severe Type 1 SLE, with active nephritis (39%), arthritis, new rashes, dsDNA+, and low C3/C4, with mild Type 2 symptoms, primarily fatigue (61%).
- **Predominantly Type 2:** Type 2 SLE (n=58): minimal Type 1 SLE and significant Type 2 symptoms including high widespread pain scores, fatigue (97%), waking unrefreshed (86%), depression (67%), cognitive dysfunction (59%).
- **Mixed SLE:** Moderate Mixed SLE (n=52): active Type 1 SLE (69% arthritis, 35% anti-dsDNA+) and active Type 2 SLE, with moderate widespread pain scores, fatigue (90%), waking unrefreshed (96%), forgetfulness (52%), and depression (49%).
- **Severe Mixed SLE** (n=24): active Type 1 SLE (54% arthritis, 25% proteinuria) combined with severe Type 2 SLE, with high widespread pain scores, depression (86%), fatigue (100%), and waking unrefreshed (100%).

**Conclusions** Patient-reported measures can be identifying distinct clusters of patients with higher and lower levels of Type 1 and 2 SLE features. We have already found this approach useful in direct clinical care and are working to identify immunologic differences between clusters and optimal management protocols.

**Funding Source(s):** None